Fast Five Quiz: Relapsed/Refractory Marginal Zone Lymphoma

Christina Poh, MD


November 03, 2021

Patients with nodal MZL who progress within 24 months of initial systemic chemoimmunotherapy should be considered for targeted therapy. Approved targeted therapies for this subtype of MZL include Bruton tyrosine kinase (BTK) inhibitors (such as ibrutinib and zanubrutinib), phosphatidylinositol 3-kinase (PI3K) inhibitors (such as idelalisib, duvelisib, copanlisib, and umbralisib), and lenalidomide in combination with rituximab. There are limited data regarding the use of autologous stem cell transplantation in nodal MZL; this treatment is not commonly used due to potential for considerable toxicity and the availability of targeted therapies.

Learn more about treatment for nodal MZL.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.